Cardiovascular and Cerebrovascular Diseases
Japan Medical explains terminology, research evidence and Japanese public records relating to regenerative medicine for cardiovascular and cerebrovascular conditions. The page is designed to help readers distinguish research registration, regulatory filing and product-specific approval. Japan Medical does not assess personal circumstances or recommend providers.
For terminology and official-source navigation only. Please do not send medical records or test results.
These figures describe disease burden only; they say nothing about any intervention’s performance.
Three Common Diagnoses
WHO describes heart attacks and strokes as acute events usually caused by a blockage of blood flow to the heart or brain [1]. These three diagnoses cover most conditions named in regenerative-medicine content.
Ischaemic Heart Disease
Plaque-narrowed coronary arteries reduce blood supply to the heart muscle; a complete blockage causes a heart attack (myocardial infarction).
Ischaemic Stroke
A blocked artery interrupts blood flow to part of the brain. It is the most common form of stroke.
Haemorrhagic Stroke
Some strokes are caused by bleeding into or around the brain rather than by a blocked vessel.
Emergency Warning Signs
Sudden facial weakness, arm weakness, speech difficulty or other possible stroke signs require immediate contact with local emergency services. For selected patients with ischemic stroke, clot-dissolving medicines may be used within 4.5 hours. Mechanical thrombectomy may be considered for selected patients for up to 24 hours, depending on imaging criteria and clinical eligibility [3].
What Regenerative Medicine Research Is Studying
Six proposed mechanisms appear repeatedly in this field. Each card states the evidence setting, what researchers measure, and what a finding does not prove.
Neural Differentiation
Evidence setting: laboratory and preclinical models. Researchers measure whether introduced cells display neural-lineage markers. A marker in a model does not prove neuron formation in the human brain, or clinical benefit.
Paracrine Signaling
Evidence setting: laboratory observation of signals that cells release. Researchers measure signaling-protein changes near injured tissue. A laboratory signal does not prove the same effect occurs meaningfully in a patient.
Angiogenesis
Evidence setting: preclinical models of vessel growth. Researchers measure new small-vessel formation near injured regions. This does not establish improved blood flow or daily function in humans.
Immune Modulation
Evidence setting: preclinical models and early human studies. Researchers measure inflammatory-marker changes after an intervention. A marker shift does not prove changes in symptoms or long-term outcomes.
Exosome Signals
Evidence setting: laboratory investigation of cell-free vesicles. Researchers measure the cargo and behavior of released vesicles. Composition and dosing remain unsettled; laboratory behavior does not establish clinical benefit.
Systemic Effects
Evidence setting: early-phase studies of whole-body responses. Researchers measure circulation- and inflammation-related markers after administration. Marker meaning remains uncertain and does not establish functional improvement.
From Laboratory Research to Public Use
Interventions usually move through recognizable stages. Not every study uses a conventional Phase 1–4 label, but each stage answers a different question [4].
Laboratory and animal research
Preclinical work examines biological plausibility in cells and animals. Preclinical findings do not establish benefit in humans [4].
Early human research
Early human studies often address initial safety, feasibility or dose-related questions rather than benefit [4].
Exploratory studies
Exploratory studies ask whether an intervention shows measurable effects in defined groups. Starting a human study does not establish effectiveness.
Confirmatory studies
Confirmatory studies test pre-specified questions in larger controlled groups. Completing a study does not mean results have been publicly posted [4].
Regulatory review and follow-up
If evidence supports an application, a regulator reviews a specific product for a specific use; monitoring continues after any approval.
Study Design Features That Change What a Result Can Show
Two studies of the same intervention can give different answers by design. These features reduce particular sources of bias, but do not guarantee that a study is large enough, correctly conducted or applicable to another population [5].
Control Group
A comparison group shows what happens without the intervention or under standard care; without one, changes cannot be attributed to the intervention [5].
Random Allocation
Assigning participants by chance helps prevent the groups from differing systematically before the study begins [5].
Masking
When participants or assessors do not know who received what, expectations are less likely to shape the outcome [5].
Prospective Protocol
A plan written before the study starts fixes the questions in advance, making later selective reporting harder [6].
Sample Size
Small studies can miss rare events and produce unstable estimates. Size alone does not fix a weak design [6].
Single vs Multicenter
Multicenter studies test whether findings hold across settings; single-center results may reflect local practice [6].
What Was the Study Actually Designed to Measure?
Before asking what a study found, ask what it was designed to measure. Outcome definitions decide what a result can show [7].
- Primary outcome — the main question the study was designed to answer [7]
- Secondary outcome — additional questions specified alongside it [7]
- Exploratory outcome — analyses that generate hypotheses
- Measurement time point — when the outcome was assessed
- Pre-specified outcome — defined before the data were seen
- Outcome added after study start — deserves extra scrutiny
- Patient-centered outcome — how a person feels or functions
- Laboratory or imaging marker — a biological measurement, not a direct experience
A change in a laboratory, imaging or biological marker is not automatically evidence that a person feels better, functions better or lives longer [8].
A Results Page Is More Than Its Headline
Nine parts of a posted results record each change how the numbers should be read [9].
- Participant flow — how many started and left at each stage
- Baseline characteristics — who the participants were
- Number completing follow-up — how much data is missing
- Primary outcome results — the answer to the main question
- Secondary outcome results — context, not the headline
- Adverse events — unfavorable changes reported
- Limitations and caveats — what the investigators flag
- Study record dates — submission and last update
- Linked publications — whether a peer-reviewed paper exists
A positive secondary or exploratory result does not erase a negative primary outcome.
Known Risks, Reported Events and Remaining Unknowns
Safety sections use precise terms; reading them loosely, in either direction, leads to wrong conclusions [6].
Adverse Event
An unfavorable health change reported during or after a study period. Its occurrence does not by itself establish that the intervention caused it [6].
Serious Adverse Event
An event meeting defined severity criteria, such as hospitalization — a regulatory category, not an impression [6].
Caused vs Coincident
An event that occurred during the study is not the same as one caused by the intervention.
Follow-Up Length
Short follow-up can miss late problems, and research involves risks that may not be fully known in advance [10].
Participant Withdrawal
Participants leaving a study can change what the remaining data mean, especially if withdrawals cluster in one group.
Missing Outcome Data
Gaps in outcome data limit what any analysis can conclude.
“No serious events were reported” is not equivalent to “no risk,” particularly when participant numbers or follow-up periods are limited [10].
Claims That Require Extra Verification
None of these signals proves dishonesty on its own; each is a reason to pause and verify. Advertising is judged on its overall impression, not only on individual sentences [11].
“Approved in Japan”
Approval is always attached to a named product. Without the exact name, the claim cannot be checked [12].
No Stated Use
Approval applies to a defined indication. A claim that omits the approved use cannot be verified [12].
Status Word Swap
Registered, listed, filed, submitted or reviewed written as approved.
Stories as Evidence
Testimonials used in place of study results [11].
Before-and-After Content
Images or anecdotes presented as proof of effect [11].
Absolute Words
Guaranteed, risk-free, safe, repair, restore or cure.
Urgency
Limited places, act now, exclusive access.
Geographic Marketing
Japan-leading, advanced Japanese technology, world-class framework.
Category-Only Naming
A cell category with no exact product name.
Percentage-Only Results
A percentage with no sample size, control group, primary outcome or follow-up.
What Each Source Can — and Cannot — Establish
Every source type answers some questions and cannot answer others.
WHO
- Can: disease definitions, global burden and risk factors [1]
- Cannot: whether a specific product or program works
ClinicalTrials.gov
MHLW Plan Database
- Can: that a provision plan was filed and published, and its contents [14]
- Cannot: that effectiveness has been demonstrated, or PMDA product approval
PMDA Documents
Peer-Reviewed Papers
- Can: what methods and results the authors reported
- Cannot alone: approval, applicability to everyone, or equal results from other preparations
Press and Promotional Pages
- Can: how the issuer describes an event
- Cannot establish: safety, effectiveness, approval status or comparative advantage [11]
Three Terms That Need Precise Definitions
These categories describe different materials and different legal statuses. They are not interchangeable.
Cell-Based Approaches
Autologous means cells originate from the same individual; allogeneic means from a donor. Autologous origin does not by itself establish safety, effectiveness or approval.
Cell-Free Approaches
Exosome-related products require separate assessment of composition, manufacturing, evidence and regulatory status; approval in one jurisdiction must not be inferred from another. The U.S. FDA has warned consumers about unapproved regenerative therapies; this is U.S. regulatory information, not an interpretation of Japanese law [16].
iPS-Cell-Derived Research
Induced pluripotent stem cells are reprogrammed from ordinary cells. For these conditions, iPS-cell-derived interventions remain at the research stage.
How to Read ClinicalTrials.gov
ClinicalTrials.gov is a public study registry. A listing does not mean that the U.S. government has reviewed or approved the study’s safety or scientific validity. Sponsors and investigators are responsible for the information they submit [13]. When reading a record, check:
- Study phase and what it is designed to answer
- Recruitment status and locations
- Exact intervention name and preparation
- Inclusion and exclusion criteria
- Comparator: placebo, standard care or none
- Primary outcome and how it is measured
- Whether results have been posted
- Reported adverse events
- Linked peer-reviewed publications
Three Different Records, Three Different Meanings
In Japan, a regenerative-medicine provision plan submitted under the Act on the Safety of Regenerative Medicine is different from PMDA marketing approval for a specific regenerative medical product. Readers should verify provision plans and approved products in separate official records [14] [12].
Clinical research registration
Registration records that a study exists; it does not evaluate its results [13].
Regenerative-medicine provision plans
Before certain cell-based procedures are provided, a plan must pass certified-committee review and be filed with the ministry. Filed plans are published in an official database [14]. Submission is a safety-oversight procedure, not an approval of effectiveness.
Conditional, time-limited approval
Japan has a conditional and time-limited approval framework for certain regenerative medical products. The regulatory status, approved indication, conditions and subsequent evidence requirements must be checked for the specific product [12].
Checking an External Webpage or Public Statement
Before accepting a webpage, advertisement or public statement, work through these items.
Exact Wording
Quote the claim precisely first.
Who Is Speaking
Identify the organization behind the statement.
Named Product
Look for an exact product name.
Named Record
Look for a study identifier, plan record or approval record.
Jurisdiction
Check which country’s rules apply.
Evidence vs Assertion
Separate linked records from unsupported claims [11].
Independent Confirmation
Confirm it in a source the claimant does not control.
Date
Check when it was made and whether records have changed since.
Who Prepared This Page and Why
Prepared and published by Japan Medical. Japan Medical is the name used for this knowledge-publishing website. It is not a hospital, clinic, laboratory, healthcare provider, referral service or treatment coordinator. Japan Medical has no physical service location and does not provide clinical services.
Japan Medical explains terminology, summarizes identified public sources and helps readers locate official study and regulatory records. Japan Medical does not diagnose conditions, interpret medical records, assess personal suitability, recommend providers, arrange appointments or coordinate care.
Last reviewed: July 28, 2026
Sources last checked: July 28, 2026
Corrections: Send a correction request via WhatsApp at +81-8070161366. Correction requests are reviewed against the cited source before the page is updated.
Sources Used on This Page
Sources are numbered in the order they first appear above. Links were checked on July 28, 2026.
- [1] WHO — Cardiovascular diseases (CVDs) fact sheet. who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- [2] WHO — The top 10 causes of death. who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
- [3] AHA/ASA — 2026 Guideline for the Early Management of Acute Ischemic Stroke (summary). ahajournals.org/doi/10.1161/STR.0000000000000513
- [4] ClinicalTrials.gov — Learn about studies. clinicaltrials.gov/study-basics/learn-about-studies
- [5] FDA — clinical trial design and conduct document. fda.gov/media/71349/download
- [6] ClinicalTrials.gov — glossary of study terms. clinicaltrials.gov/study-basics/glossary
- [7] ClinicalTrials.gov — how to read a study record. clinicaltrials.gov/study-basics/how-to-read-study-record
- [8] FDA — surrogate endpoint resources. fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development
- [9] ClinicalTrials.gov — how to read study results. clinicaltrials.gov/study-basics/how-to-read-study-results
- [10] HHS (OHRP) — informed consent tips. hhs.gov/ohrp/regulations-and-policy/guidance/informed-consent-tips/index.html
- [11] FTC — Health Products Compliance Guidance. ftc.gov/business-guidance/resources/health-products-compliance-guidance
- [12] PMDA (Japan) — approved products information. pmda.go.jp/english/review-services/reviews/approved-information/0004.html
- [13] ClinicalTrials.gov — disclaimer on study listings. clinicaltrials.gov/about-site/disclaimer
- [14] MHLW (Japan) — submitted provision plans database. saiseiiryo.mhlw.go.jp/published_plan
- [15] PMDA (Japan) — review services and review reports. pmda.go.jp/english/review-services/reviews/0003.html
- [16] FDA — consumer information about regenerative medicine therapies (U.S. regulatory information, not an interpretation of Japanese law). fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
- [17] PMDA (Japan) — safety information for cell- and tissue-based products. pmda.go.jp/english/safety/info-services/ctp/0001.html
Frequently Asked Questions
What does regenerative medicine research mean?
It means studying whether cell-based or cell-free interventions can limit damage caused by disease. Most applications for these conditions remain at the preclinical or early clinical stage, and mechanistic findings do not by themselves establish benefit.Does a registered study or filed provision plan mean that a product is approved?
No. Registration, filing and approval are three different records. The registry and Japan records sections above explain each one.
How can I check a claim against official records?
Identify the exact product and its intended use, then look for the study identifier in ClinicalTrials.gov, the plan in the health ministry’s database, or the approval record in PMDA’s documents. If none exists, ask for the record in writing.
What is the difference between a primary and a secondary outcome?
The primary outcome is the main question a study was designed to answer; secondary outcomes are additional specified questions. A positive secondary result does not erase a negative primary outcome.
Why can a completed study have no public results?
Completion only means data collection finished. Results posting can lag, and some studies never post results. The record’s dates and results tab show what is public.
Where can I find the full scope of Japan Medical?
See the About Japan Medical section for the full scope and limitations of this website.
Need Help Understanding a Source?
Ask Japan Medical about terminology, study records, regulatory documents or citation paths. Please do not send medical records, test results or other sensitive personal information.
For terminology and official-source navigation only.